Last reviewed · How we verify

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate

Universitaire Ziekenhuizen KU Leuven · FDA-approved active Small molecule

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate is a Combination sedative-antipsychotic Small molecule drug developed by Universitaire Ziekenhuizen KU Leuven. It is currently FDA-approved for Acute agitation and psychotic episodes (historical use), Sedation in psychiatric settings (historical use).

This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously.

This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously. Used for Acute agitation and psychotic episodes (historical use), Sedation in psychiatric settings (historical use).

At a glance

Generic nameValium + Akineton + Dehydrobenzperidol + Atropine sulfate
SponsorUniversitaire Ziekenhuizen KU Leuven
Drug classCombination sedative-antipsychotic
TargetGABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaPsychiatry/Neurology
PhaseFDA-approved

Mechanism of action

Valium (diazepam) is a benzodiazepine that enhances GABA inhibitory neurotransmission; Akineton (biperiden) is an anticholinergic agent that blocks muscarinic receptors; Dehydrobenzperidol is a butyrophenone antipsychotic blocking dopamine D2 receptors; and Atropine sulfate is an anticholinergic that further blocks muscarinic acetylcholine receptors. Together, these agents produce profound CNS depression, antipsychotic activity, and anticholinergic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Valium + Akineton + Dehydrobenzperidol + Atropine sulfate

What is Valium + Akineton + Dehydrobenzperidol + Atropine sulfate?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate is a Combination sedative-antipsychotic drug developed by Universitaire Ziekenhuizen KU Leuven, indicated for Acute agitation and psychotic episodes (historical use), Sedation in psychiatric settings (historical use).

How does Valium + Akineton + Dehydrobenzperidol + Atropine sulfate work?

This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously.

What is Valium + Akineton + Dehydrobenzperidol + Atropine sulfate used for?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate is indicated for Acute agitation and psychotic episodes (historical use), Sedation in psychiatric settings (historical use).

Who makes Valium + Akineton + Dehydrobenzperidol + Atropine sulfate?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate is developed and marketed by Universitaire Ziekenhuizen KU Leuven (see full Universitaire Ziekenhuizen KU Leuven pipeline at /company/universitaire-ziekenhuizen-ku-leuven).

What drug class is Valium + Akineton + Dehydrobenzperidol + Atropine sulfate in?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate belongs to the Combination sedative-antipsychotic class. See all Combination sedative-antipsychotic drugs at /class/combination-sedative-antipsychotic.

What development phase is Valium + Akineton + Dehydrobenzperidol + Atropine sulfate in?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate is FDA-approved (marketed).

What are the side effects of Valium + Akineton + Dehydrobenzperidol + Atropine sulfate?

Common side effects of Valium + Akineton + Dehydrobenzperidol + Atropine sulfate include Sedation/drowsiness, Anticholinergic effects (dry mouth, urinary retention, constipation), Hypotension, Extrapyramidal side effects, Respiratory depression.

What does Valium + Akineton + Dehydrobenzperidol + Atropine sulfate target?

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate targets GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor and is a Combination sedative-antipsychotic.

Related